HEBERPROT-P contains human epidermal growth factor which is produced by recombinant DNA technology. When directly injected into the wound, this growth factor ensures healing of deep and serious diabetic foot ulcers that are induced by diabetes and may usually lead to amputation of the foot. It has gained an important place among the treatments of diabetic foot ulcers and those addressing the prevention of diabetes-induced foot amputation (removal). When applied to diabetic foot ulcers associated with impaired blood flow into the tissue or nerve damage, HEBERPROT-P provides a fast, safe and effective wound healing process. In addition, HEBERPROT-P has significantly reduced the rates of foot amputation caused by diabetes-induced foot ulcers in 26 countries where it is already registered.